Please login to read the full article.
Scrip Regulatory Affairs
EMA to make public side-effects in EudraVigilance database by end of 2011
15 July 2011
Vibha Sharma
Please login to read the full article.
Not a subscriber ? Request a FREE Trial
Subscribe to Regulatory Affairs Pharma
RELATED CONTENT
NEWS
Scrip Regulatory Affairs News
- EMA policy on allowing access to EudraVigilance data imminent
- UK consults on transposing EU pharmacovigilance rules into national law
- BEMA benchmarking scheme for EU drug agencies enters cycle III; medical devices might be on horizon
- Draft EU regulation sets out uniform conditions for various pharmacovigilance activities
Other Informa News
ANALYSIS
Regulatory Affairs Pharma Analysis
Other Informa Analysis
EDITORIALS
Regulatory Affairs Pharma Editorials
Other Informa Editorials
FEATURES
Regulatory Affairs Pharma Features
Other Informa Features
COMMENT
Regulatory Affairs Pharma Comment
Other Informa Comments
